Crown Bioscience Brings Top Scientists Together
News Oct 03, 2015
Crown Bioscience hosted a symposium earlier this month for some of the industry’s leading experts to discuss the latest scientific discoveries in translational oncology.
“Some of the foremost researchers in this field shared information about immuno-oncology therapies and their impact on translational oncology,” said Christopher Murriel, Ph.D., who chaired the event in San Diego. A senior scientist in department of cancer biology at OncoMed Pharmaceuticals, he spoke at the symposium about the use of patient-derived and murine tumor models to predict impacts on cancer stem cells and anti-tumor immunity.
“Translational research, particularly in oncology, holds tremendous potential toward therapeutic drug development and clinical advancement - and the scientists at this symposium presented exciting research that demonstrates how much opportunity exists,” said Murriel. Using clinically-relevant models, Crown Bioscience helps researchers make the best decisions to speed the optimum drug candidates to clinical development.
“We’re pleased to share our expertise and sponsor this forum for scientists and clinicians to discuss the merits of current and future approaches,” said Jean-Pierre Wery, Ph.D., resident of Crown Bioscience. “Our goal is to spur change by helping the industry translate preclinical research into medicines to improve the health and quality of life of patients.”
Henry Li, Ph.D., vice president of translational oncology at Crown Bioscience, discussed the molecular pathway of patient-derived xenograft diseases. Tommy Broudy, Ph.D., general manager and chief scientific officer at Crown Bioscience San Diego, spoke about the adoption of clinically relevant models in oncology therapeutics.
Chief scientists from Decoy Biosystems, Tragara Pharmaceuticals, ImmunGene, Regulus Therapeutics, Ignyta and Pfizer also spoke.
Crown Bioscience will host another symposium Nov. 4 in Boston; details will soon be provided.
Reversing an Unstoppable Cancer Cascade with ProteomicsNews
Mutations in genes that produce RAS proteins turn a normally benign process, essential for cellular growth, into a cancer stimulant that is currently undruggable. Now, cutting-edge protein analysis may help treat cancers caused by these mutations.READ MORE
A New, Streamlined Approach to Diagnosing and Treating Bowel CancerNews
Researchers at the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide have discovered a faster, more cost-effective way to determine which DNA mutations cause human bowel cancer.READ MORE
Protein "Shield" Affects Responses to Breast Cancer DrugNews
BRCA-positive breast cancers arise from a cell's failure to accurately repair its DNA. A study analyzing the complex network of DNA repair molecules has discovered a new group of proteins which affect response to some first-line breast cancer drugs.READ MORE
Comments | 0 ADD COMMENT
29th International Conference on Public Mental Health and Neuroscience
Jul 16 - Jul 18, 2018
International Conference on Epigenetics and Epitranscriptomics
Sep 17 - Sep 18, 2018